The relationship between XRCC1 gene polymorphism and the efficacy and prognosis of TACE in patients with hepatocellular carcinoma in Nantong area
10.3969/j.issn.1006-2483.2021.05.023
- VernacularTitle:南通地区XRCC1基因多态性与肝癌患者TACE疗效及预后关系
- Author:
Xiaohua LU
1
;
Hongxin YUAN
1
;
Hui ZHAO
1
;
Xiaoqing ZHU
1
Author Information
1. Department of Interventional Radiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
- Publication Type:Journal Article
- Keywords:
XRCC1 gene;
Polymorphism;
Hepatocellular carcinoma;
Hepatocellular carcinoma
- From:
Journal of Public Health and Preventive Medicine
2021;32(5):101-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between the genotypes of XRCC1 gene C26304T , G27466A, G28152A and the efficacy and prognosis of hepatocellular carcinoma in Nantong area. Methods The Genomic DNA was extracted from 252 newly diagnosed liver cancer patients admitted to the Department of Interventional Radiology, Affiliated Hospital of Nantong University from January 1, 2018 to December 31, 2018, and relevant clinical data and abdominal enhanced CT/MRI data were collected. Genotyping was performed using Panel high-throughput data analysis. All patients received TACE treatment, and abdominal enhanced CT/MRI was reexamined 4-6 weeks after treatment, and the efficacy was evaluated according to the efficacy of RECIST solid tumor. Survival of participants was followed up by telephone after 15 months. The frequency distribution differences of different genotypes in the efficacy and prognosis of different TACE treatments were compared, and the strength of association between related genotypes and the efficacy and prognosis of HCC TACE was indicated by odds ratio (OR) and its 95% confidence interval (CI). Results 1. The efficacy of TACE was better in AG patients with XRCC1 G28152A heterozygous mutation (OR=0.294, 95%CI:0.053-0.987), while there was no significant difference between patients with homozygous AA and patients with wild-type GG (OR=1.334, 95%CI:0.123-8.545). There was no significant difference in the efficacy of TACE between C26304T and G27466A genotypes. 2. Compared with the patients with wild-type GG, patients with G28152A heterozygous mutation AG were more likely to survive for 15 months and had a better prognosis after TACE (OR=0.262, 95%CI:0.051-0.988), but there was no significant difference in survival time between patients with homozygous mutation AA and patients with wild-type GG (OR=2.180, 95％CI:0.312-12.743）.There was no significant difference in survival time between the genotypes of C26304T and G27466A. Conclusion The patients with liver cancer in Nantong who carried heterozygous mutation AG at G27466A site of XRCC1 gene had better curative effect and prognosis of TACE. SNPs at C26304T and G28152A sites had no significant correlation with curative effect and prognosis of TACE.
